<DOC>
	<DOC>NCT00468546</DOC>
	<brief_summary>This study will assess the safety and efficacy of rituximab combined with MTX in participants with active rheumatoid arthritis (RA) who have had an inadequate response to anti-Tumor Necrosis (TNF) alpha therapy. The anticipated time in the study is up to 2 years and the target sample size is 500 participants. Eligible participants may receive re-treatment with rituximab under a separate protocol WA17531.</brief_summary>
	<brief_title>A Study to Evaluate the Safety and Efficacy of MabThera (Rituximab) in Combination With Methotrexate (MTX) in Participants With Active Rheumatoid Arthritis Who Failed on Anti-Tumor Necrosis Factor Alpha Therapy</brief_title>
	<detailed_description />
	<mesh_term>Arthritis</mesh_term>
	<mesh_term>Arthritis, Rheumatoid</mesh_term>
	<mesh_term>Rituximab</mesh_term>
	<mesh_term>Methotrexate</mesh_term>
	<criteria>Adult participants 1880 years of age with active RA for at least 6 months; Received treatment for RA on an outpatient basis and experienced an inadequate response or intolerance to treatment with at least 1 antiTNF alpha therapy (etanercept, infliximab or adalimumab); Must have received MTX for a minimum of 12 weeks, with the last 4 weeks, prior to screening at a stable dose; Participants with swollen joint count (SJC) and tender joint count (TJC) of at least 8 joints at screening and at randomization; Radiographic evidence of at least 1 joint with a definite erosion due to RA; Participants of reproductive potential must be using reliable contraceptive methods. Bone or joint surgery within 8 weeks prior to screening or joint surgery planned within 24 weeks of randomization; Class IV functional status of RA; Previous treatment within 6 months with intravenous gamma globulin, or the Prosorba column; Intraarticular or parenteral corticosteroids within 4 weeks prior to screening visit; With a live vaccine within 4 weeks prior to randomization; Previous treatment with rituximab or other celldepleting therapies; Concurrent treatment with any diseasemodifying antirheumatic drug (except for MTX) or any antiTNF alfa factor or other biologic therapy; History of severe allergic or anaphylactic reactions to humanized or murine monoclonal antibodies; Evidence of significant uncontrolled concomitant diseases such as cardiovascular disease, nervous system, pulmonary, renal, hepatic, endocrine or gastrointestinal disorders; Known contraindications to receiving rituximab; Known active bacterial, viral, fungal, mycobacterial or other infection; History of recurrent significant infection or history of recurrent bacterial infections; Primary or secondary immunodeficiency (history of, or currently active); History of cancer, including solid tumors and hematologic malignancies (except basal cell or squamous cell carcinoma of the skin that have been excised and cured); Women who are pregnant or breastfeeding; History of alcohol, drug or chemical abuse within 6 months prior to screening; Neuropathies and neurovasculopathies which might interfere with pain evaluation; Participants with poor peripheral venous access; Intolerance or contraindications to oral or intravenous corticosteroids.</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>80 Years</maximum_age>
	<verification_date>August 2016</verification_date>
</DOC>